SIGX 1094R
Alternative Names: SIGX-1094; SIGX-1094RLatest Information Update: 22 Jan 2025
Price :
$50 *
At a glance
- Originator Signet Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Focal adhesion protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 18 Dec 2024 Preclinical trials in Solid tumours in China (PO)
- 18 Dec 2024 Signet Therapeutics plans phase-I trial for Solid tumours (Monotherapy, Late-stage disease, Metastatic disease) in China (PO) in December 2024 (NCT06739291)
- 12 Dec 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in China (PO) (NCT06739291)